Updated on 9 May 2012
Among other developments, the company is progressing with its plans to start the first human clinical trial of rotavirus vaccine. It is also about to start the phase I trial for the typhoid polysaccharide in the next few months. The company is also in the process of developing a hexavalent vaccine.
As the first Indian company to launch an r-DNA hepatitis B vaccine, Shanvac B, in 1997, Shantha heralded a new beginning for biotechnology and affordable healthcare in India. The Indian company continues to push boundaries and transcend limitations, bolstered by its research-driven scientific ethos. Shantha spends 24 percent of its revenue for R&D each year.
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
1Comment
Comment 1 - 1 of 1
hemen parekh 5 July 2012 at 11 AM
A drop in the Ocean ? India’s Health Minister, Ghulam Nabi Azad wants Indian medical students to sign a bond , before going to USA , that they will return to India after finishing their higher studies Why ? Because India is short of doctors He is right. Here are figures for numbers of doctors per 10,000 population ( 2000 – 2010 ), published in World Health Statistics – 2011: India …………………… 6.0 China …………………. 14.2 UK ………………………. 27.4 USA …………………… 26.7 Question : Will forcing 1,000 medical students [ who do not return after higher studies abroad every year ], make a drop of difference to our Ocean of Ill-health ? No doubt , Minister of Health knows best ! With regards hemen parekh www.CustomizeResume.com Jobs for All = Peace on Earth
Reply